Notícias

Novo Nordisk (NYSE:NVO) has updated the Wegovy label in Singapore to include new STEP UP trial data for adults with obesity. The label change reflects clinically meaningful benefits observed in the STEP UP study for semaglutide in obesity treatment. The update comes as obesity drug developers draw fresh attention from investors, including renewed buyout speculation around peers such as Viking Therapeutics. Novo Nordisk, trading at $48.89, sits at the center of renewed interest in obesity...

The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is the default healthcare allocation for millions of investors, and for good reason. XLV owns the entire S&P 500 healthcare complex in one ticker: insurers, device makers, biotech, and Big Pharma. It has returned 21.61% over the past year and 159.84% over ten years. If the reason ... Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%

Vivani Medical’s new agreement gives Novo Nordisk (CPSE:NOVO B) access to evaluate NPM-139, a semaglutide implant for chronic weight management, offering investors another data point on the company’s obesity drug delivery options. See our latest analysis for Novo Nordisk. The Vivani agreement lands at a time when Novo Nordisk’s DKK323.15 share price has shown strong short term momentum, with a 30 day share price return of 18.81% and a 90 day share price return of 35.72%. Over longer periods,...

Prothena shares climb as late-stage partnered programs advance, milestone payments strengthen finances and its neurodegenerative pipeline continues to expand.

Viking Therapeutics' expanding obesity pipeline and upcoming VK2735 data reignite buyout speculation as investors weigh its growing strategic appeal.

The GLP-1 trade has matured from a single-stock story into a tiered opportunity set. Demand for obesity therapeutics keeps expanding as lower-cost, easier-to-administer oral pill versions of the current injectable GLP-1s are introduced to the market in 2026, and the field now spans an entrenched leader, a deep-value incumbent, and a clinical-stage challenger with multiple ... 3 High Growth GLP-1 Biotech Winners to Buy in July

By Rishika Sadam July 9 (Reuters) - Danish drugmaker Novo Nordisk launched its weekly basal insulin injection, Awiqli, in India on Thursday, aiming to compete with daily-dose options on the market. 

July 9 (Reuters) - Shares of Dr Reddy's Laboratories fell as much as 6.5% on Thursday, after the Indian drugmaker said it is delaying commercial supplies of semaglutide due to an issue related to the

It's been about five years since the U.S. Food and Drug Administration approved Wegovy for chronic weight management, but semaglutide, the active ingredient in Ozempic and similar drugs, goes back much further. Semaglutide was first synthesized in 2008 after scientists found that saliva extracted ...

Novo Nordisk (NVO) reached $48.89 at the closing of the latest trading day, reflecting a -1.51% change compared to its last close.

Shares in Novo Nordisk (NYSE:NVO) fell 2.5% to DKK319.20 after Deutsche Bank pointed to a continued slowdown in the oral version of the company's Wegovy weight-loss drug in the US. The bank published its weekly tracker of prescription data for Novo's GLP-1 franchise, the class of...

Eli Lilly hits another record high as confidence grows in its obesity and diabetes portfolio, with Wall Street still seeing upside despite the rich valuation.

UBS has reiterated its overweight stance on European pharmaceuticals, framing the sector as a more resilient home for capital than artificial intelligence at a point when the wider market is slowing. The bank argued that the investment case now rests on more than defensive quality. It...

Vivani’s NanoPortal technology delivers medication steadily over long periods of time.

Microsoft Corporation (NASDAQ:MSFT) is one of the Best Software Stocks to Buy in 2026. Recently, on July 2, Reuters reported that Microsoft Corporation (NASDAQ:MSFT) is launching a new company called Microsoft Frontier, with the aim of helping businesses choose and integrate AI technologies that actually fit their needs and generate real returns. As per the […]

Don't sleep on these medical device leaders.

The stock is down, but it isn't out yet.

Novo Nordisk and Vivani Medical are collaborating to evaluate a semaglutide drug implant using Vivani’s NanoPortal platform for chronic weight management. Vivani has initiated a Phase 1 clinical study of the implant, while Novo Nordisk assesses semaglutide in this drug delivery format. The partnership focuses on an implantable GLP-1 approach that could offer an alternative to pills and injections for obesity treatment. Novo Nordisk, traded as CPSE:NOVO B, is already a central player in...

Eli Lilly shares hit a record high Tuesday after IPO stock Kailera Therapeutics posted lackluster test results for its weight-loss pill.

July 7 (Reuters) - The weight-loss drug market is booming, with biotech firms racing to capture a slice of a fast-growing sector dominated by Novo Nordisk and Eli Lilly.

Agios stock skyrocketed closer to a profit-taking zone Tuesday after the FDA assigned its sickle cell drug a speedy review.

AZN targets continued 2026 growth with expanding blockbuster medicines, a strong pipeline and 2030 revenue goals as it outpaces Pfizer on key metrics.

Healthcare has become Wall Street’s bargain bin in 2026, and value hunters are starting to pay attention. Drug pricing reform, patent cliffs and post-COVID-19 hangovers have crushed multiples across Big Pharma, but the wreckage has created opportunities in two cash-generative franchises trading at single-digit forward earnings multiples. Heading into July, Novo Nordisk and Pfizer stand ... 2 Dirt Cheap Healthcare Stocks to Buy in July

The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.

European stocks are having their loudest year in a decade, and the Vanguard FTSE Europe ETF (NYSEARCA:VGK) is the vehicle most retail investors will consider. VGK trades around $90, up 18% over the past year, while every US finance headline focuses on hyperscaler capex and AI compute. If you want to bet that the next ... The Anti-Magnificent Seven Trade? VGK Is Quietly Creeping Toward Record Highs

Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.

European equities traded in the US as American depositary receipts were tracking modestly higher lat

The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.

Peptides are short-chain amino acids that are formulated into drugs. Insulin is a peptide. Legions of other peptides are on the market in the “wellness” industry, promoted for everything from athletic performance to skin care, mental focus, and “romantic connection”—the latter pitched by a startup called Feel Peptides.

This biotech might have a bright future, but it'll need to survive against the incumbents to do so.